Novavax, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $56.7M | $139.5M | $147.1M | $70.4M | $239.2M | $666.7M | $88.3M | $84.5M |
| Cost of Revenue | $14.2M | $30.7M | $22.1M | $21.5M | $15.3M | $14.1M | $36.7M | $60.6M |
| Gross Profit | $42.5M | $108.8M | $125.0M | $48.9M | $223.9M | $652.5M | $51.6M | $23.9M |
| Gross Margin | 74.9% | 78.0% | 85.0% | 69.5% | 93.6% | 97.9% | 58.5% | 28.3% |
| Operating Expenses | ||||||||
| Research & Development | $70.7M | $95.5M | $75.9M | $98.3M | $79.2M | $88.9M | $104.4M | $87.2M |
| SG&A Expense | $26.7M | $28.8M | $34.1M | $31.7M | $43.6M | $48.1M | $78.3M | $70.7M |
| Operating Income | $-54.9M | $-15.4M | $14.2M | $-178.0M | $101.1M | $515.5M | $-131.1M | $-134.0M |
| Operating Margin | -96.8% | -11.1% | 9.7% | -252.7% | 42.2% | 77.3% | -148.4% | -158.6% |
| Interest Expense | $4.5M | $3.7M | $3.3M | $3.0M | $2.6M | $2.6M | $1.1M | $2.6M |
| Pretax Income | $-51.7M | $-8.5M | $17.9M | $-203.0M | $107.5M | $519.8M | $-73.6M | $-122.3M |
| Income Tax Expense | $1.7M | $985.0K | $376.0K | $-657.0K | $946.0K | $1.2M | $7.4M | $-1.0M |
| Net Income | $-53.4M | $-9.5M | $17.5M | $-202.4M | $106.5M | $518.6M | $-81.0M | $-121.3M |
| Net Margin | -94.2% | -6.8% | 11.9% | -287.3% | 44.5% | 77.8% | -91.8% | -143.5% |
| EPS (Basic) | $-0.32 | $-0.06 | $0.09 | $-1.25 | $0.66 | $3.22 | $-0.51 | $-0.76 |
| EPS (Diluted) | $-0.32 | $-0.06 | $0.28 | $-1.25 | $0.62 | $2.93 | $-0.41 | $-0.76 |
| Shares Outstanding (Basic) | 164.6M | 163.3M | 162.0M | 162.4M | 162.0M | 161.0M | 152.2M | 160.0M |
| Shares Outstanding (Diluted) | 164.6M | 163.3M | 173.1M | 162.4M | 177.2M | 177.6M | 152.2M | 160.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |